Posted by Michael Wonder on 17 Feb 2021
Sandoz Canada completes its fifth biosimilar launch with new biosimilar Hyrimoz (adalimumab)
16 February 2021 - Hyrimoz for use in nine indications covered by the reference medicine in the fields of rheumatology, gastro-enterology and dermatology.
Sandoz Canada announced today the launch of Hyrimoz (adalimumab injection, reference biologic drug: Humira), which was authorised for sale in Canada by Health Canada on 4 November 2020 as one of the four Sandoz biosimilars to be authorised in Canada in the last 11 months.
Hyrimoz is indicated for the treatment of nine of the twelve life-threatening or serious debilitating conditions in adults and children covered by the reference medicine, including the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, psoriasis and adult uveitis.
